Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)

被引：1
|
作者：
Hankosky, Emily R.
Desai, Karishma
Chinthammit, Chanadda
Grabner, Michael
Stockbower, Grace
He, Xuanyao
Mojdami, Donna
Wenziger, Cachet
Gibble, Theresa Hunter
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-2084-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2084-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [41] REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPEL™ STUDY
    Mody, R.
    Huang, Q.
    Yu, M.
    Zhang, X.
    Wang, L.
    Grabner, M.
    Patel, H.
    VALUE IN HEALTH, 2019, 22 : S149 - S150
  • [42] Baseline Characteristics and Real-world Treatment Patterns in People with T2D in India: Results from iCaReMe Registry
    Saboo, B.
    Kadam, Y.
    Vasnawala, H.
    Bharath, H.
    Sarda, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [43] Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2
    Galindo, Rodolfo J.
    Garvey, W. Timothy
    Neff, Lisa M.
    Stefanski, Adam
    Cao, Dachuang
    Lee, Clare
    DIABETES, 2024, 73
  • [44] A Retrospective Real-World Study of Dapagliflozin vs. Other Oral Antidiabetic Therapies Added to Metformin in Patients with Type 2 Diabetes (T2D)
    Huang, Huan
    Bell, Kelly
    Gani, Ray
    Tugwell, Cathy
    Eudicone, James
    Krukas, Michelle
    DIABETES, 2017, 66 : A330 - A330
  • [45] Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured US Population
    Mody, Reema
    Desai, Karishma
    Teng, Chia-Chen
    Reznor, Gally
    Stockbower, Grace
    Grabner, Michael
    Benneyworth, Brian D.
    DIABETES, 2024, 73
  • [46] Effort Reward Imbalance (ERI) among Workers with Type 2 Diabetes (T2D)
    Olesen, Kasper
    Cleal, Bryan
    Willaing, Ingrid
    DIABETES, 2016, 65 : A219 - A219
  • [47] REASSESSMENT OF A REAL-WORLD POPULATION OF ADULTS WITH TYPE 2 DIABETES (T2D): WHEN LOW LEVELS OF C-PEPTIDE OR PRESENCE OF DIABETES AUTOANTIBODIES MIGHT INDICATE POSSIBLE TYPE 1 DIABETES (T1D)
    Aguilar, D.
    Yuan, G.
    Wade, R. L.
    Lu, J.
    Raupp, M.
    Lichtenstein, M.
    VALUE IN HEALTH, 2020, 23 : S348 - S348
  • [48] Cost-Effectiveness of Insulin Icodec for the Treatment of Type 2 Diabetes (T2D) in Canada
    Garcia, David A.
    Mau, Godfrey
    Vuong, Vivian
    Singh, Sumeet
    Jensen, Morten S.
    Goldenberg, Ronald
    DIABETES, 2024, 73
  • [49] Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database
    Stoyanova, D.
    Stratmann, B.
    Schwandt, A.
    Heise, N.
    Muehldorfer, S.
    Ziegelasch, H-J
    Zimmermann, A.
    Tschoepe, D.
    Holl, R. W.
    DIABETIC MEDICINE, 2020, 37 (08) : 1291 - 1298
  • [50] Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Baseline BMI
    Kis, Janos T.
    Seufert, Jochen
    Haluzik, Martin
    Vera, Carine
    Tournay, Mathilde
    Bonnemaire, Mireille
    Freemantle, Nick
    Guja, Cristian
    DIABETES, 2024, 73
12345